|
As a leader in the global scientific and medical community, Stanford Medicine continues to pioneer new approaches to understanding and treating melanoma. With a better grasp of how and why normal melanocytes become melanoma, more effective therapies are now possible.
By drawing upon discoveries made in the basic sciences: biochemistry, immunology, engineering and physics, we are "translating" these advances into changes in the management of melanoma. This collaboration between basic scientists and clinician investigators forges a bridge between the scientific research bench to the patient's bedside.
Translational Medicine/Laboratory Correlate Studies (involves blood or tissue collection from melanoma patients)
|
Study Title
|
Principal Investigator
|
|
Characterization of Tumor-Specific T Cells in Melanoma and in Healthy and Vitiligo Controls; Cancer-induced Immune Dysfunction in Melanoma; Biology of Tumor Infiltrating Lymphocytes: Analysis and Manipulation of T cell Response to Cancer
|
Peter Lee, MD, PhD
|
|
Tumor Infiltrating Immune Responses in Cancer Patients; T-cell Functionality and Anti-melanoma Immune Responses
|
Mark Davis, MD
|
|
Prospective Isolation of the Cancer Stem Cell in Melanoma Patients
|
Irving Weissman, MD
|
|
Susceptibility to Skin Cancer: Assessment of Abnormal Transcriptional Response in Melanoma Patients
|
Gilbert Chu, MD
|
|
Genetic Alterations Related to Induction of Melanocytic Neoplasia in Human Tissue
|
Paul Khavari, MD, PhD
|
|
Multi-gene Approach to Improve the Diagnosis and Prognosis of Cutaneous Melanoma; Role of Tumor Lymphangiogenesis in Predicting Nodal and Systemic Metastasis in Patients with Primary Cutaneous Melanoma
|
Soheil Dadras, MD, PhD
|
|
Creation of a Melanocytic Tumor Tissue Microarray for Studies Comparing Potential Diagnostic, Prognostic, and Therapeutic-related Markers in Benign versus Malignant Melanocytic Neoplasms
|
David Cassarino, MD, PhD
|
|
